Literature DB >> 15523900

Detection of 22q11.2 deletion among 139 patients with Di George/Velocardiofacial syndrome features.

S Kitsiou-Tzeli1, A Kolialexi, H Fryssira, A Galla-Voumvouraki, K Salavoura, M Kanariou, G Th Tsangaris, E Kanavakis, A Mavrou.   

Abstract

Cytogenetic and FISH analysis was performed in 139 patients to detect the pathognomonic of Di George/ Velocardiofacial syndrome (DGS/VFCS) deletion 22q11.2. An abnormal karyotype was revealed in 2/139 cases (47, XXY and 46, XX, 2p+). A deletion was found in 17/139 (12.2%) patients (14 males/ 3 females), inherited in 3 (2 maternal and 1 paternal). Patients with 22q11.2 deletion exhibited facial dysmorphic features (82%), congenital heart defects (70%), immunological problems (47%), multiple congenital anomalies (64%), hypocalcemia (47%), mental retardation/learning difficulties (35%), cleft palate/velopharyngeal insufficiency (23.5%), seizures/hypotonia (23%) and growth retardation (12%). Among 56/139 patients with detailed available clinical data, the 22q11.2 deletion was confirmed in all cases with hypocalcemia and in over half of the cases with multiple congenital anomalies, immunological problems and hypotonia/seizures (70%, 60% and 57%, respectively). Genetic reevaluation of 39 patients without the 22q11.2 deletion contributed to the classification of 14 (37%) under different syndromes, emphasizing the need for stricter referral criteria.

Entities:  

Mesh:

Year:  2004        PMID: 15523900

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

1.  Neonatal Levels of T-cell Receptor Excision Circles (TREC) in Patients with 22q11.2 Deletion Syndrome and Later Disease Features.

Authors:  Kiran A Gul; Torstein Øverland; Liv Osnes; Lars O Baumbusch; Rolf D Pettersen; Kari Lima; Tore G Abrahamsen
Journal:  J Clin Immunol       Date:  2015-03-27       Impact factor: 8.317

2.  Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature.

Authors:  Fabíola P Monteiro; Társis P Vieira; Ilária C Sgardioli; Miriam C Molck; Ana Paula Damiano; Josiane Souza; Isabella L Monlleó; Marshall I B Fontes; Agnes C Fett-Conte; Têmis M Félix; Gabriela F Leal; Erlane M Ribeiro; Claudio E M Banzato; Clarissa de R Dantas; Iscia Lopes-Cendes; Vera Lúcia Gil-da-Silva-Lopes
Journal:  Eur J Pediatr       Date:  2013-02-26       Impact factor: 3.183

Review 3.  The 22q11.2 Microdeletion in Pediatric Patients with Cleft Lip, Palate, or Both and Congenital Heart Disease: A Systematic Review.

Authors:  Diana Cárdenas-Nieto; Maribel Forero-Castro; Clara Esteban-Pérez; Julio Martínez-Lozano; Ignacio Briceño-Balcázar
Journal:  J Pediatr Genet       Date:  2019-10-23

4.  Histology of the pharyngeal constrictor muscle in 22q11.2 deletion syndrome and non-syndromic children with velopharyngeal insufficiency.

Authors:  Josine C C Widdershoven; Nicole E Spruijt; Wim G M Spliet; Corstiaan C Breugem; Moshe Kon; Aebele B Mink van der Molen
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

Review 5.  22q11 deletion syndrome: current perspective.

Authors:  Bülent Hacıhamdioğlu; Duygu Hacıhamdioğlu; Kenan Delil
Journal:  Appl Clin Genet       Date:  2015-05-18

6.  General approach to velocardiofacial anomalies: a pediatric case presenting with Fallot tetralogy.

Authors:  Aysu Turkmen Karaagac; Ayse Inci Yildirim
Journal:  North Clin Istanb       Date:  2015-01-24

7.  Characteristic face: a key indicator for direct diagnosis of 22q11.2 deletions in Chinese velocardiofacial syndrome patients.

Authors:  Dandan Wu; Yang Chen; Chen Xu; Ke Wang; Huijun Wang; Fengyun Zheng; Duan Ma; Guomin Wang
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

8.  The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation.

Authors:  Andrean L Simons; Ping Lu; Katherine N Gibson-Corley; Robert A Robinson; David K Meyerholz; John D Colgan
Journal:  Lab Invest       Date:  2013-04-22       Impact factor: 5.662

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.